|  | HER2 +  | χ2 analysis p-value | Univariate analysis |  |
---|---|---|---|---|---|
 |  |  |  | OR (CI 95%)a | p-value |
No. of patients | Â | 5 | Â | Â | Â |
Tumour size | Median (mm) Range (mm) | 25 12–36 |  |  |  |
 ≥ 2 cm |  | 3/5 | 0.885 | 1.184 (0.192–7.316) | 0.856 |
T2 intensity | Hypointensity Isointensity Hyperintensity | 3/5 2/5 0/5 | 0.322 | 1.844 (0.299–11.39) 2.081 (0.333–12.99) Out of scale | 0.510 0.433 |
Mass enhancement | Â | 5/5 | 0.268 | Out of scale | Â |
Rim enhancement | Â | 0/5 | 0.087 | Out of scale | Â |
Intralesional necrosis |  | 1/5 | 0.285 | 0.317 (0.034–2.908) | 0.309 |
Perilesional oedema | Â | 0/5 | 0.017 | Out of scale | Â |
Abnormal lymph nodes |  | 2/5 | 0.910 | 1.111 (0.180–6.875) | 0.910 |
Intensity-to-time curve | Type I Type II Type III | 0/5 1/5 4/5 | 0.720 | Out of scale 0.721 (0.078–6.674) 2.112 (0.230–19.442) | 0.774 0.509 |
ADC value | Very low Low Intermediate | 4/5 1/5 0/5 | 0.681 | 2.575 (0.279–23.75) 0.417 (0.045–3.845) Out of scale | 0.404 0.440 |
Extent of disease | Unifocal Multifocal Multicentric | 2/5 2/5 1/5 | 0.857 | 0.796 (0.129–4.915) 1.658 (0.267–10.31) 0.721 (0.078–6.674) | 0.806 0.588 0.774 |